查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2045924

眼科藥物市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、適應症、產品類型、劑型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Ophthalmic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class By Indication By Product Type By Dosage Form By Route of Administration By Distribution Channel By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球眼科藥品市場預計將從 2025 年的 462.4 億美元成長到 2031 年的 634.3 億美元，複合年成長率為 5.41%。

這些特殊配方對於診斷、治療和管理多種影響眼部前段和後段的眼科疾病至關重要，包括青光眼、乾眼症和視網膜疾病。推動這一市場發展的主要因素是全球人口老化以及糖尿病等文明病的日益增多，這些疾病顯著增加了視力障礙的風險。眼科疾病率的不斷上升推動了對有效治療方法的持續需求。國際防盲協會（IAPB）預測，到2025年，全球將有超過10億人遭受可預防或可治療的視力喪失，凸顯了藥物治療方案的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 462.4億美元
市場規模：2031年 634.3億美元
複合年成長率：2026-2031年 5.41%
成長最快的細分市場 抗發炎藥
最大的市場 北美洲

然而，該市場面臨一個重大障礙：眼科新療法的監管核准流程複雜且成本高昂。開發能夠有效穿透眼部保護屏障的藥物需要大量資金和大規模臨床試驗來驗證其安全性和有效性。這些嚴格的監管要求，加上高昂的研發成本，構成了一道巨大的准入壁壘，減緩了新治療方法的商業化進程，並阻礙了整個市場的成長。

市場促進因素

推動市場發展的主要因素是生物製藥和基因療法的突破性湧現。這些療法正在重新定義治療方法，從單純的症狀管理轉向直接干預疾病本身。這種轉變體現在高特異性抗體和創新基因傳遞系統的快速發展上，這些療法為視網膜疾病帶來了卓越的療效和持久的療效。這些最先進治療對市場產生了重大影響，上市後迅速佔據了較大的市場佔有率，同時保持高價。例如，根據2025年1月報告，羅氏的新型雙特異性抗體Vabysmo在2024年的銷售額達到39億瑞士法郎，凸顯了市場對先進生物製藥的強勁臨床需求。同樣，根據2025年2月報道，再生元製藥的EYLEA系列藥物在2024年於美國實現了59.7億美元的淨銷售額，進一步強調了生物製藥療法在全球的商業性實力。

同時，慢性眼疾和老齡化性眼科疾病（尤其是老齡化黃斑部病變(AMD) 和糖尿病視網膜病變）日益普遍，正顯著的推動市場擴張。隨著全球人口老化，視力障礙疾病的發生率不斷上升，增加了對持續藥物治療的需求，並加速了新核准治療方法的應用。日益加重的疾病負擔直接轉化為患者對有效治療方法的強烈需求，為市場成長創造了有利環境。例如，Astellas來製藥的 Izervay（據 2025 年 2 月報告）在 2024 年 10 月至 11 月期間，約占美國新患者的 60%，這表明存在巨大的未滿足需求。

市場挑戰

全球眼科藥物市場面臨的一大挑戰是新眼科治療方法核准流程的嚴格性和高昂成本。開發能夠有效穿透眼部複雜結構（例如血液視網膜屏障）的製劑，需要精密的藥物遞送系統和大量的安全性資料。這些嚴格的要求迫使製造商在產品獲得核可階段之前進行長期的臨床試驗並投入大量前期資金。這種高進入門檻對小規模的生技公司影響尤其顯著，這些公司往往缺乏足夠的財力來應對漫長的法規核准流程，導致市場競爭減弱，整體創新速度放緩。

臨床試驗的高失敗率加劇了這項挑戰，限制了整體市場擴張。企業被迫承擔因候選藥物失敗而產生的巨額沉沒成本，阻礙了對可能具有突破性但風險極高的後段眼疾治療方法的投資。這種研發路徑中固有的困難在整個生物製藥產業普遍存在，並直接影響眼科領域的研發策略。美國製藥製造商協會（PhRMA）在2025年強調了藥物研發的極高風險，指出只有12%的新分子實體最終能夠獲得監管部門的核准。如此低的成功率迫使製藥公司採取極其謹慎的策略，從而限制了新眼科藥物的研發管線，並阻礙了市場成長。

市場趨勢

關鍵趨勢之一是緩釋眼內給藥系統的應用。這些系統正在改變市場格局，有效解決了患者每日滴眼治療依從性低這一重大難題。這其中包括微創前房植入的商業化，可確保對青光眼等慢性疾病進行持續治療，從而有效穩定眼壓，而無需依賴患者的依從性。這些設備的快速市場接受度凸顯了臨床上對持久有效、減少患者用藥次數的治療方法的強烈需求。例如，根據2025年10月的報告，Glaukos公司的緩釋前房植入iDose TR僅在2025年第三季就實現了約4000萬美元的淨銷售額，這表明這項給藥技術創新具有巨大的商業性價值。

同時，老花眼藥物的出現使市場關注點從控制病情轉向改善生活品質。這一趨勢標誌著一個重要的轉折點，因為縮瞳眼藥水正擴大被用作矯正眼鏡之外的非侵入性治療方案，以解決與老齡化相關的近視問題，吸引了大量希望擺脫眼鏡束縛的患者。製藥公司正積極瞄準這個以消費者主導的市場，並實施直接互動策略以加速產品普及。 Orasis Pharmaceuticals 的直接面對消費者的宣傳活動就是一個典型的例子。根據 2025 年 11 月的一份報告，自 Qlosi 上市以來，該公司的宣傳活動已獲得超過一百萬次的點擊量，這表明患者對這類新型療法表現出極高的興趣。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球眼科藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（抗發炎藥、抗感染藥、抗過敏藥、抗青光眼藥、其他）
    • 適應症（乾眼症、眼睛過敏、青光眼、眼睛感染疾病、其他）
    • 產品類型（成藥和療法）
    • 劑型（凝膠、軟膏、眼藥水、錠劑/膠囊）
    • 給藥途徑（局部、眼部、全身）
    • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美眼科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲眼科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區眼科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲眼科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲眼科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球眼科藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Horizon Therapeutics plc
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ocular Therapeutix, Inc.
  • Sun Pharmaceutical Industries Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7633

The global ophthalmic drugs market is projected to expand from USD 46.24 billion in 2025 to USD 63.43 billion by 2031, demonstrating a compound annual growth rate of 5.41%. These specialized pharmaceutical formulations are crucial for the diagnosis, treatment, and management of various eye conditions affecting the anterior and posterior segments, including glaucoma, dry eye disease, and retinal disorders. The market's main driver is the escalating global aging population, coupled with a rise in lifestyle-related illnesses such as diabetes, which substantially increase the risk of vision impairment. This rising incidence of eye diseases fuels a continuous demand for effective treatments, with over one billion people worldwide experiencing preventable or treatable sight loss in 2025, according to the International Agency for the Prevention of Blindness, underscoring the vital need for pharmacological solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 46.24 Billion
Market Size 2031USD 63.43 Billion
CAGR 2026-20315.41%
Fastest Growing SegmentAnti-Inflammatory Drugs
Largest MarketNorth America

Nevertheless, the market faces a considerable hurdle in the form of the complex and expensive regulatory approval process for new ocular therapeutics. The development of drugs capable of effectively penetrating the eye's protective barriers demands substantial capital and extensive clinical trials to prove both safety and efficacy. Such stringent regulatory demands, combined with high R&D costs, present significant entry barriers that can slow the commercialization of new treatments and hinder overall market growth.

Market Driver

The primary market driver is the transformative rise of biologics and gene therapies, which are redefining treatment approaches from mere symptom management to interventions that modify the disease itself. This shift is evident in the swift adoption of advanced bispecific antibodies and innovative gene delivery systems, delivering superior efficacy and lasting benefits for retinal conditions. These cutting-edge therapeutics have a considerable market impact, commanding high prices and rapidly securing significant market share post-launch. For example, Roche's novel bispecific antibody Vabysmo generated 3.9 billion Swiss Francs in 2024 sales, as reported in January 2025, highlighting the strong clinical demand for advanced biologics. Similarly, Regeneron Pharmaceuticals' EYLEA franchise achieved $5.97 billion in U.S. net sales for 2024, reported in February 2025, further emphasizing the commercial strength of biological treatments globally.

Concurrently, the increasing prevalence of chronic and age-related ocular conditions, especially age-related macular degeneration (AMD) and diabetic retinopathy, significantly propels market expansion. With a growing global elderly population, the incidence of vision-impairing disorders is escalating, driving the need for ongoing pharmacological care and boosting the adoption of newly approved therapies. This heightened disease burden directly translates into strong patient demand for effective treatments, fostering a favorable climate for market growth, as exemplified by Astellas Pharma's Izervay capturing roughly 60% of new U.S. patient starts for geographic atrophy between October and November 2024, reported in February 2025, indicating a substantial unmet need.

Market Challenge

A significant challenge for the Global Ophthalmic Drugs Market is the demanding and costly regulatory approval process for new ocular therapies. Creating formulations that can effectively penetrate the eye's intricate structures, such as the blood-retina barrier, requires sophisticated drug delivery systems and extensive safety data. These strict requirements compel manufacturers to undertake lengthy clinical trials and make substantial initial financial investments even before a product reaches the approval phase. This formidable entry barrier disproportionately impacts smaller biotechnology companies, which often lack the financial resources to endure prolonged regulatory delays, thus decreasing market competition and slowing overall innovation.

This challenge is further compounded by the high likelihood of clinical failures, which constrains overall market expansion. Companies must absorb considerable sunk costs from unsuccessful drug candidates, deterring investment in potentially groundbreaking, yet riskier, treatments for posterior segment disorders. The inherent difficulty of this development path is reflected across the broader biopharmaceutical industry, directly influencing ophthalmic R&D strategies. In 2025, the Pharmaceutical Research and Manufacturers of America highlighted the extreme risk in drug development, noting that only 12% of new molecular entities entering clinical trials ultimately gain regulatory approval. This low success rate forces pharmaceutical companies to be highly selective, consequently limiting the pipeline of novel ophthalmic drugs and impeding market growth.

Market Trends

A key trend is the adoption of sustained-release ocular drug delivery systems, which are transforming the market by resolving the crucial issue of patient non-adherence to daily topical treatments. This involves the commercialization of minimally invasive, intracameral implants that ensure continuous therapeutic dosing for chronic conditions such as glaucoma, effectively stabilizing intraocular pressure without depending on patient compliance. The rapid market acceptance of these devices highlights a strong clinical demand for long-lasting, burden-reducing interventions. For instance, Glaukos Corporation's iDose TR, a prolonged-release intracameral implant, achieved approximately $40 million in net sales in the third quarter of 2025 alone, as reported in October 2025, showcasing the immediate commercial significance of this delivery innovation.

Concurrently, the introduction of pharmacological treatments for presbyopia is broadening the market's focus from managing pathology to enhancing lifestyle. This trend signifies a major shift where miotic eye drops are increasingly used as a non-invasive substitute for corrective lenses to address age-related near-vision loss, thereby accessing a large patient demographic seeking freedom from spectacles. Pharmaceutical companies are actively targeting this consumer-driven segment with direct engagement strategies to accelerate adoption. This demand is exemplified by Orasis Pharmaceuticals' direct-to-consumer campaigns, which generated over 1 million clicks to learn about Qlosi since its launch, as reported in November 2025, indicating substantial patient interest in this new therapeutic class.

Key Market Players

  • Novartis AG
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Horizon Therapeutics plc
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ocular Therapeutix, Inc.
  • Sun Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Ophthalmic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ophthalmic Drugs Market, By Drug Class

  • Anti-Inflammatory Drugs
  • Anti-Infection Drugs
  • Anti-Allergic Drugs
  • Anti-Glaucoma Drugs
  • Others

Ophthalmic Drugs Market, By Indication

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Eye Infection
  • Others

Ophthalmic Drugs Market, By Product Type

  • OTC Drugs
  • Prescription Drugs

Ophthalmic Drugs Market, By Dosage Form

  • Gels
  • Ointments
  • Eye Solutions
  • Eye Drops
  • Tablets & Capsules

Ophthalmic Drugs Market, By Route of Administration

  • Topical
  • Ocular
  • Systemic

Ophthalmic Drugs Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Ophthalmic Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ophthalmic Drugs Market.

Available Customizations:

Global Ophthalmic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ophthalmic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Anti-Inflammatory Drugs, Anti-Infection Drugs, Anti-Allergic Drugs, Anti-Glaucoma Drugs, Others)
    • 5.2.2. By Indication (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Others)
    • 5.2.3. By Product Type (OTC Drugs v/s Prescription Drugs)
    • 5.2.4. By Dosage Form (Gels, Ointments, Eye Solutions, Eye Drops, Tablets & Capsules)
    • 5.2.5. By Route of Administration (Topical, Ocular, Systemic)
    • 5.2.6. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Ophthalmic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Indication
    • 6.2.3. By Product Type
    • 6.2.4. By Dosage Form
    • 6.2.5. By Route of Administration
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ophthalmic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Product Type
        • 6.3.1.2.4. By Dosage Form
        • 6.3.1.2.5. By Route of Administration
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Canada Ophthalmic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Product Type
        • 6.3.2.2.4. By Dosage Form
        • 6.3.2.2.5. By Route of Administration
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Mexico Ophthalmic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Product Type
        • 6.3.3.2.4. By Dosage Form
        • 6.3.3.2.5. By Route of Administration
        • 6.3.3.2.6. By Distribution Channel

7. Europe Ophthalmic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Indication
    • 7.2.3. By Product Type
    • 7.2.4. By Dosage Form
    • 7.2.5. By Route of Administration
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ophthalmic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Product Type
        • 7.3.1.2.4. By Dosage Form
        • 7.3.1.2.5. By Route of Administration
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. France Ophthalmic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Product Type
        • 7.3.2.2.4. By Dosage Form
        • 7.3.2.2.5. By Route of Administration
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. United Kingdom Ophthalmic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Product Type
        • 7.3.3.2.4. By Dosage Form
        • 7.3.3.2.5. By Route of Administration
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. Italy Ophthalmic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Product Type
        • 7.3.4.2.4. By Dosage Form
        • 7.3.4.2.5. By Route of Administration
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Ophthalmic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Product Type
        • 7.3.5.2.4. By Dosage Form
        • 7.3.5.2.5. By Route of Administration
        • 7.3.5.2.6. By Distribution Channel

8. Asia Pacific Ophthalmic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Indication
    • 8.2.3. By Product Type
    • 8.2.4. By Dosage Form
    • 8.2.5. By Route of Administration
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ophthalmic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Product Type
        • 8.3.1.2.4. By Dosage Form
        • 8.3.1.2.5. By Route of Administration
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. India Ophthalmic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Product Type
        • 8.3.2.2.4. By Dosage Form
        • 8.3.2.2.5. By Route of Administration
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. Japan Ophthalmic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Product Type
        • 8.3.3.2.4. By Dosage Form
        • 8.3.3.2.5. By Route of Administration
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. South Korea Ophthalmic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Product Type
        • 8.3.4.2.4. By Dosage Form
        • 8.3.4.2.5. By Route of Administration
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Ophthalmic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Product Type
        • 8.3.5.2.4. By Dosage Form
        • 8.3.5.2.5. By Route of Administration
        • 8.3.5.2.6. By Distribution Channel

9. Middle East & Africa Ophthalmic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Indication
    • 9.2.3. By Product Type
    • 9.2.4. By Dosage Form
    • 9.2.5. By Route of Administration
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ophthalmic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Product Type
        • 9.3.1.2.4. By Dosage Form
        • 9.3.1.2.5. By Route of Administration
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. UAE Ophthalmic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Product Type
        • 9.3.2.2.4. By Dosage Form
        • 9.3.2.2.5. By Route of Administration
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. South Africa Ophthalmic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Product Type
        • 9.3.3.2.4. By Dosage Form
        • 9.3.3.2.5. By Route of Administration
        • 9.3.3.2.6. By Distribution Channel

10. South America Ophthalmic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Indication
    • 10.2.3. By Product Type
    • 10.2.4. By Dosage Form
    • 10.2.5. By Route of Administration
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ophthalmic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Product Type
        • 10.3.1.2.4. By Dosage Form
        • 10.3.1.2.5. By Route of Administration
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Colombia Ophthalmic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Product Type
        • 10.3.2.2.4. By Dosage Form
        • 10.3.2.2.5. By Route of Administration
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. Argentina Ophthalmic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Product Type
        • 10.3.3.2.4. By Dosage Form
        • 10.3.3.2.5. By Route of Administration
        • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ophthalmic Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc.
  • 15.3. Bausch Health Companies Inc.
  • 15.4. Santen Pharmaceutical Co., Ltd.
  • 15.5. Regeneron Pharmaceuticals, Inc.
  • 15.6. Horizon Therapeutics plc
  • 15.7. Pfizer Inc.
  • 15.8. F. Hoffmann-La Roche Ltd.
  • 15.9. Ocular Therapeutix, Inc.
  • 15.10. Sun Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer